ClinicalTrials.gg
TerminatedNCT04119453Updated Jul 30, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

A Phase 2 interventional study of Rivoceranib in Adenoid Cystic Carcinoma, sponsored by Elevar Therapeutics. Terminated at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Elevar Therapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
The RM-202 study was terminated by the Sponsor due to redirection of the rivoceranib development plan.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies in Carcinoma, Adenoid Cystic with a site in United States — 11 open to participants now, 21 under way, none of them phase 3. Carcinoma, Adenoid Cystic · United States.

Enrollment
13th of 43
80 · median 38
Started
2020
with 3 others
Phase 2
23 of 45
3 open now
Registered
22nd of 45
by date

Among the 45 studies in Carcinoma, Adenoid Cystic with a site in United States, this one is the 13th largest by enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2020, is one of 23 in phase 2, and was the 22nd registered.

Carcinoma, Adenoid Cystic

86 studies on the registry are indexed under Carcinoma, Adenoid Cystic; 26 are open to participants now.

Browse Carcinoma, Adenoid Cystic studies →

Open to participants now

11 of the 45 studies in Carcinoma, Adenoid Cystic with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Carcinoma, Adenoid Cystic studies recruiting now, 15 (65%) set no upper age limit and 3 (13%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Carcinoma, Adenoid Cystic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of rivoceranib in adult participants with recurrent or metastatic ACC. All participants may remain on treatment until occurrence of disease progression, unacceptable toxicity, death, the withdrawal of consent from treatment, lost to follow-up or study termination by the Sponsor. When a participant discontinues rivoceranib for any reason, the participant will enter the 24 month survival follow up period until withdrawal of consent from the study, lost to follow up, end of the study or death, whichever occurs earlier.

The maximum duration of the study is estimated to be 48 months and includes screening, treatment, and follow-up phases.

03

Conditions studied

  • Adenoid Cystic Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed /recurrent ACC not amenable to potentially curative surgery or radiotherapy
  2. Evidence of disease progression by v1.1

    Note: Disease progression is defined as one of the following occurring within the 6 months prior to study entry:

    1. At least a 20% increase in radiologically or clinically
    2. Appearance of any new lesions
  3. Presence of at least one measurable target lesion which is evaluable by RECIST v1.1 criteria
  4. Participants are eligible if central nervous system (CNS) metastases have been treated and participants are neurologically returned to baseline or neurologically stable in the opinion of Investigator (except for residual signs or symptoms related to the CNS treatment) for at least 4 weeks prior to first dose of study drug administration. In addition, participants must be either off , or on a stable dose or decreasing dose of \<20 milligrams (mg) daily prednisone or prednisone equivalent.

    Note: Only participants with a known history or indication of CNS disease are required to have CNS imaging prior to study entry

  5. Adequate organ and marrow function within 14 days prior to the first dose of rivoceranib administration, defined as:

    1. ≥1500/microliters (μL)
    2. count ≥100,000/μL
    3. Serum ≤1.5× (ULN)
    4. (AST) and alanine aminotransferase (ALT) ≤3.0×ULN (≤5.0×ULN, if with liver metastasis)
    5. Estimated >50 milliliters (mL)/minute (min) (Cockcroft-Gault)
    6. (PTT), prothrombin time (PT) and international normalized ratio (INR) ≤1.5×ULN
    7. ≥9.0 grams (g)/deciliter (dL)
  6. Urinary protein \<2+ on dipstick or routine urinalysis. If urine dipstick or routine analysis indicates proteinuria ≥2+, a 24-hour urine or urine protein/creatinine ratio must be collected and must demonstrate \<2 g of protein in 24 hours.
  7. (ECOG) performance status of 0 or 1
  8. The ability to understand and the willingness to sign a written
  9. Female participants who are of non- (that is, by history - no menses for ≥1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Female participants of must have a negative serum pregnancy test within 72 hours prior to the first dose of rivoceranib.
  10. Male and female participants of reproductive potential who agree to use both a highly effective method of (for example, implants, injectables, combined oral contraceptives, some intrauterine devices, complete abstinence, or sterilized partner) and a barrier method (for example condoms, cervical ring, sponge, etc.) during the period of therapy and for 30 days after the final dose of rivoceranib. Female participants should also refrain from breastfeeding and egg donation and males should refrain from sperm donation throughout this period
  11. \<480 milliseconds (ms) ( [CTCAE] Grade 1) using Fredericia's QT correction formula

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with rivoceranib
  2. Known to rivoceranib or components of the formulation
  3. Packed red blood cell transfusion or erythropoietin therapy within 14 days prior to the first dose of rivoceranib administration
  4. History of another within 3 years prior to enrollment. A participant with the following malignancies is eligible for this study if, surgically and medically treated and in the opinion of the investigator, they do not pose a significant risk to or not likely to recur within 3 years:

    1. Carcinoma of the skin without melanomatous features
    2. Curatively treated cervical carcinoma in situ
    3. Bladder tumors considered superficial such as noninvasive (T1a) and carcinoma in situ (Tis)
    4. Thyroid papillary cancer with prior treatment
    5. Prostate cancer which has been surgically or medically treated
  5. Prior chemotherapy, radiation therapy or major surgery within 4 weeks prior to rivoceranib administration or presence of any nonhealing wound (procedures such as catheter placement are not considered to be major surgery). Prior immunotherapy within 12 weeks prior to first dose of study drug. Palliative radiotherapy to non-target lesions within 2 weeks prior to rivoceranib administration or any time prior to rivoceranib administration is permitted.
  6. Prior tyrosine kinase inhibitor therapy targeting vascular endothelial growth factor receptors (VEGFR), within 5 half-lives prior to rivoceranib administration
  7. Participants who have not recovered to ≤Grade 1 from prior tyrosine kinase inhibitor-related adverse events
  8. History of uncontrolled hypertension based on Investigator's clinical judgement (consistent blood pressure readings ≥140/90 millimeters of mercury [mmHg] and/or change in antihypertensive medication within 7 days prior to rivoceranib administration)
  9. History of severe adverse events including uncontrolled hypertension or other common anti-angiogenesis class drug effects (for example, ramucirumab) that may indicate a higher risk to the safety of the participant if provided further anti-angiogenesis treatment, in the investigator's opinion.
  10. History of vascular disease including arterial or venous embolic events (pulmonary embolism), other than hypertension, within the last 3 months prior to treatment with rivoceranib (for example, hypertensive crisis, hypertensive encephalopathy, stroke or [TIA], or significant peripheral vascular diseases) that, in the investigator's opinion, may pose a risk to the participant on vascular endothelial growth factor (VEGF) inhibitor therapy.
  11. History of bleeding diathesis or bleeding within 14 days prior to treatment with rivoceranib
  12. History of clinically significant thrombosis within 3 months prior to treatment with rivoceranib that, in the investigator's opinion, may place the participant at risk of side effects from anti-angiogenesis products
  13. Therapy with systemic anticoagulant or antithrombotic agents within 7 days prior to treatment with rivoceranib that in the investigator's opinion could interfere with clotting. The maximum allowable daily dose of aspirin is 325 mg.
  14. Gastrointestinal malabsorption, or any other condition that in the opinion of the investigator might affect the absorption of rivoceranib
  15. History of clinically significant glomerulonephritis, biopsy-proven tubulointerstitial nephritis, crystal nephropathy, or other renal insufficiencies
  16. An uncontrolled intercurrent illness including, but not limited to any of the following:

    1. Ongoing or active infection (including minor localized infections) requiring oral or intravenous treatment
    2. Symptomatic class 3 or 4 congestive heart failure, defined as a clinical syndrome resulting from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood
    3. Unstable angina pectoris
    4. Cardiac arrhythmia
    5. Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the participant's safety or study endpoints
  17. A female participant who is pregnant or breast-feeding
  18. Psychiatric illness/social situations that would limit compliance with study requirements
  19. History of drug or alcohol abuse within the past 5 years
  20. Known seropositive requiring anti-viral therapy for (HIV) infection
  21. Known seropositive requiring antiviral therapy for virus (HBV) infection OR evidence of active hepatitis B infection by detectable viral load if the antibody tests are positive NOTE: A positive hepatitis B core antibody (HBcAb) participant with an undetectable surface antigen and negative hepatitis B deoxyribonucleic acid (DNA) test (for example, polymerase chain reaction [PCR] test) can be enrolled.
  22. Known seropositive requiring antiviral therapy for virus (HCV) infection OR participants with positive hepatitis C virus antibody NOTE: A positive Anti-HCV participant with an undetectable/negative hepatitis C ribonucleic acid (RNA) test can be enrolled.
  23. Participation in another clinical study with any medication or product administered within ≤28 days prior to first dose of rivoceranib
  24. Participants unable or unwilling to discontinue excluded medications for at least 5 half-lives prior to first dose of study drug
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Rivoceranib

    Participants will receive an oral dose of rivoceranib once per day during 28-day cycles.

    Drug: Rivoceranib

Interventions

  • Film-coated tablets

    Also known as: Apatinib, Apatinib Mesylate

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR): Percentage of Participants Who Achieved Confirmed Complete Response (CR) or Partial Response (PR) Per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator/Institutional Assessment

    Complete Response - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm) (the sum may not be "0" if there are target nodes). Partial Response - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to 41 months

  2. ORR: Percentage of Participants Who Achieve Confirmed CR or PR Per RECIST 1.1 by Independent Central Review

    CR - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (the sum may not be "0" if there are target nodes). PR - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to 41 months

Secondary outcomes

  1. Overall Survival (OS) Rate

    OS was defined as the interval from the start of study therapy to death from any cause. Here, the percentage of participants with OS at specified time points are shown.

    Time frame: Months 12 and 24

  2. Progression Free Survival (PFS) Rate at 6 Months, 12 Months, and 2 Years by Investigator or Institutional Assessment

    PFS was defined as the time from the start of treatment with rivoceranib to the first evaluation showing Progressive Disease (PD) or death, whichever occurred first. Participants who did not experience PD or death were censored at the date of last disease assessment. Here, the percentage of participants with PFS at the given timepoints is shown. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)

    Time frame: Months 6, 12, and 24

  3. Progression Free Survival (PFS) at 6 Months, 12 Months, and 2 Years Evaluated by Independent Central Review

    PFS was defined as the time from the start of treatment with rivoceranib to the first evaluation showing PD or death, whichever occured first. Participants who do not experience PD or death were censored at the date of last disease assessment. Here, the percentage of participants with PFS at the given timepoints is shown. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)

    Time frame: Months 6 and 12, and Year 2

  4. Duration of Response (DoR) Per RECIST Version 1.1 by Investigator or Institutional Assessment

    Duration of response was the time from the first response of PR or CR (which was subsequently confirmed) to the first evaluation showing PD or death, whichever occurred first. Death due to any cause was considered in the determination of DOR. CR - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (the sum may not be "0" if there are target nodes). PR - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)

    Time frame: Up to 41 months

  5. Duration of Response (DoR) Per RECIST Version 1.1 Evaluated by Independent Central Review

    Duration of response was the time from the first response of PR or CR (which was subsequently confirmed) to the first evaluation showing PD or death, whichever occurred first. Death due to any cause was considered in the determination of DOR. CR - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (the sum may not be "0" if there are target nodes). PR - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)

    Time frame: Up to 41 months

  6. Time to Progression (TTP) Per RECIST Version 1.1 by Investigator or Institutional Assessment

    TTP was the length of time from the start of treatment with rivoceranib until objective tumor progression. At the time of analysis of TTP, any participants who do not experience PD including participants who died without PD were censored at the date of last disease assessment. The TTP was estimated using the Kaplan-Meier method. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)

    Time frame: Up to 41 months

  7. TTP Per RECIST Version 1.1 Evaluated by Independent Central Review

    TTP was the length of time from the start of treatment with rivoceranib until objective tumor progression. At the time of analysis of TTP, any participants who do not experience PD including participants who died without PD were censored at the date of last disease assessment. The TTP was estimated using the Kaplan-Meier method. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)

    Time frame: Up to 41 months

  8. Number of Participants With Treatment-Emergent Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A summary of non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: From first dose of rivoceranib until 30 days after the last dose date of rivoceranib or initiation of other anticancer therapy, whichever is earlier (up to 41 months)

07

Results

Posted Jul 30, 2026

Participant flow

Participant flow — Overall Study
MilestoneRivoceranib
Started80
Received at least 1 dose of study drug80
Completed0
Not completed80
Withdrew: Death44
Withdrew: Withdrawal by subject10
Withdrew: Study terminated by sponsor12
Withdrew: Other reasons14

Outcome measures

PrimaryObjective Response Rate (ORR): Percentage of Participants Who Achieved Confirmed Complete Response (CR) or Partial Response (PR) Per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator/Institutional Assessment

Complete Response - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm) (the sum may not be "0" if there are target nodes). Partial Response - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Up to 41 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR): Percentage of Participants Who Achieved Confirmed Complete Response (CR) or Partial Response (PR) Per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator/Institutional Assessment
percentage of participantsRivoceranib
Objective Response Rate (ORR): Percentage of Participants Who Achieved Confirmed Complete Response (CR) or Partial Response (PR) Per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator/Institutional Assessment13.8 (7.1 to 23.3)
PrimaryORR: Percentage of Participants Who Achieve Confirmed CR or PR Per RECIST 1.1 by Independent Central Review

CR - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (the sum may not be "0" if there are target nodes). PR - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Up to 41 months
Reported as:
Number · percentage of participants
ORR: Percentage of Participants Who Achieve Confirmed CR or PR Per RECIST 1.1 by Independent Central Review
percentage of participantsRivoceranib
ORR: Percentage of Participants Who Achieve Confirmed CR or PR Per RECIST 1.1 by Independent Central Review8.8 (3.6 to 17.2)
SecondaryOverall Survival (OS) Rate

OS was defined as the interval from the start of study therapy to death from any cause. Here, the percentage of participants with OS at specified time points are shown.

Time frame:
Months 12 and 24
Reported as:
Number · percentage of participants
Overall Survival (OS) Rate
percentage of participantsRivoceranib
Month 1274.7 (62.9 to 83.3)
Month 2451.5 (39.2 to 62.4)
SecondaryProgression Free Survival (PFS) Rate at 6 Months, 12 Months, and 2 Years by Investigator or Institutional Assessment

PFS was defined as the time from the start of treatment with rivoceranib to the first evaluation showing Progressive Disease (PD) or death, whichever occurred first. Participants who did not experience PD or death were censored at the date of last disease assessment. Here, the percentage of participants with PFS at the given timepoints is shown. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)

Time frame:
Months 6, 12, and 24
Reported as:
Number · percentage of participants
Progression Free Survival (PFS) Rate at 6 Months, 12 Months, and 2 Years by Investigator or Institutional Assessment
percentage of participantsRivoceranib
Month 674.1 (62.1 to 82.9)
Month 1237.3 (22.5 to 49.0)
Month 248.9 (3.3 to 17.9)
SecondaryProgression Free Survival (PFS) at 6 Months, 12 Months, and 2 Years Evaluated by Independent Central Review

PFS was defined as the time from the start of treatment with rivoceranib to the first evaluation showing PD or death, whichever occured first. Participants who do not experience PD or death were censored at the date of last disease assessment. Here, the percentage of participants with PFS at the given timepoints is shown. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)

Time frame:
Months 6 and 12, and Year 2
Reported as:
Number · percentage of participants
Progression Free Survival (PFS) at 6 Months, 12 Months, and 2 Years Evaluated by Independent Central Review
percentage of participantsRivoceranib
Month 678.3 (66.0 to 86.6)
Month 1237.4 (24.6 to 50.2)
SecondaryDuration of Response (DoR) Per RECIST Version 1.1 by Investigator or Institutional Assessment

Duration of response was the time from the first response of PR or CR (which was subsequently confirmed) to the first evaluation showing PD or death, whichever occurred first. Death due to any cause was considered in the determination of DOR. CR - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (the sum may not be "0" if there are target nodes). PR - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)

Time frame:
Up to 41 months
Reported as:
Median · months
Duration of Response (DoR) Per RECIST Version 1.1 by Investigator or Institutional Assessment
monthsRivoceranib
Duration of Response (DoR) Per RECIST Version 1.1 by Investigator or Institutional Assessment14.9 (4.9 to NA)
SecondaryDuration of Response (DoR) Per RECIST Version 1.1 Evaluated by Independent Central Review

Duration of response was the time from the first response of PR or CR (which was subsequently confirmed) to the first evaluation showing PD or death, whichever occurred first. Death due to any cause was considered in the determination of DOR. CR - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (the sum may not be "0" if there are target nodes). PR - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)

Time frame:
Up to 41 months
Reported as:
Median · months
Duration of Response (DoR) Per RECIST Version 1.1 Evaluated by Independent Central Review
monthsRivoceranib
Duration of Response (DoR) Per RECIST Version 1.1 Evaluated by Independent Central Review7.2 (3.5 to 8.4)
SecondaryTime to Progression (TTP) Per RECIST Version 1.1 by Investigator or Institutional Assessment

TTP was the length of time from the start of treatment with rivoceranib until objective tumor progression. At the time of analysis of TTP, any participants who do not experience PD including participants who died without PD were censored at the date of last disease assessment. The TTP was estimated using the Kaplan-Meier method. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)

Time frame:
Up to 41 months
Reported as:
Median · months
Time to Progression (TTP) Per RECIST Version 1.1 by Investigator or Institutional Assessment
monthsRivoceranib
Time to Progression (TTP) Per RECIST Version 1.1 by Investigator or Institutional Assessment9.2 (8.5 to 13.7)
SecondaryTTP Per RECIST Version 1.1 Evaluated by Independent Central Review

TTP was the length of time from the start of treatment with rivoceranib until objective tumor progression. At the time of analysis of TTP, any participants who do not experience PD including participants who died without PD were censored at the date of last disease assessment. The TTP was estimated using the Kaplan-Meier method. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)

Time frame:
Up to 41 months
Reported as:
Median · months
TTP Per RECIST Version 1.1 Evaluated by Independent Central Review
monthsRivoceranib
TTP Per RECIST Version 1.1 Evaluated by Independent Central Review9.3 (8.5 to 13.6)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A summary of non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
From first dose of rivoceranib until 30 days after the last dose date of rivoceranib or initiation of other anticancer therapy, whichever is earlier (up to 41 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs)
ParticipantsRivoceranib
Number of Participants With Treatment-Emergent Adverse Events (AEs)80

Adverse events

Collected over From first dose of rivoceranib until 30 days after the last dose date of rivoceranib or initiation of other anticancer therapy, whichever is earlier (up to 41 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivoceranib44/80 (55%)32/80 (40%)80/80 (100%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventRivoceranib
PneumothoraxRespiratory, thoracic and mediastinal disorders4/80
EpistaxisRespiratory, thoracic and mediastinal disorders3/80
PneumoniaInfections and infestations3/80
Back painMusculoskeletal and connective tissue disorders3/80
StomatitisGastrointestinal disorders2/80
FatigueGeneral disorders2/80
Non-cardiac chest painGeneral disorders2/80
Decreased appetiteMetabolism and nutrition disorders2/80
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/80
DyspnoeaRespiratory, thoracic and mediastinal disorders1/80
Most frequent other events
Showing 10 of 284
Most frequent other events
EventRivoceranib
HypertensionVascular disorders53/80
FatigueGeneral disorders49/80
NauseaGastrointestinal disorders43/80
HeadacheNervous system disorders42/80
StomatitisGastrointestinal disorders40/80
DiarrhoeaGastrointestinal disorders35/80
ProteinuriaRenal and urinary disorders32/80
Decreased appetiteMetabolism and nutrition disorders30/80
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders27/80
ConstipationGastrointestinal disorders25/80

Baseline characteristics

The Safety Population included all enrolled participants who received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)Rivoceranib
Mean53.5 ± 11.78
Sex: Female, Male
Sex: Female, Male(Participants)Rivoceranib
Female38
Male42
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rivoceranib
Hispanic or Latino7
Not Hispanic or Latino72
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rivoceranib
American Indian or Alaska Native0
Asian28
Native Hawaiian or Other Pacific Islander0
Black or African American2
White47
More than one race3
Unknown or Not Reported0
08

Study locations

11 sites
  • University of California, Los Angeles (UCLA)
    Los Angeles, California 90095, United States
  • UCSF
    San Francisco, California 94143, United States
  • University of Colorado Denver
    Denver, Colorado 80204, United States
  • H. Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida 33612, United States
  • Dana-Farber Cancer Institute - Head and Neck Oncology
    Boston, Massachusetts 02215, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • National Cancer Center
    Goyang-si, Gyeonggi-do, South Korea
  • Asan Medical Center
    Seoul, Gyeonggi-do, South Korea
  • Seoul National University Hospital
    Seoul, Gyeonggi-do, South Korea
  • Samsung Medical Center
    Seoul, South Korea
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Jun 2023, 41 months.

Results were first posted in Jul 2026, 3 years 1 month after primary completion. A results delay was requested in Jun 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2019
First posted
Oct 8, 2019
StartActual
Jan 22, 2020
Primary completionActual
Jun 28, 2023
CompletionActual
Jun 28, 2023
Results delay requested
Jun 21, 2024
Results first posted
Jul 30, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04119453
Lead sponsor
Elevar Therapeutics
Responsible party
Sponsor
First posted
Oct 8, 2019
Start date
Jan 22, 2020
Primary completion
Jun 28, 2023
Completion
Jun 28, 2023
Results posted
Jul 30, 2026
Last update
Jul 30, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apatinib

Start the discussion